TG Therapeutics Valuation
| TGTX Stock | USD 34.55 3.40 10.91% |
At this time, the company appears to be overvalued. TG Therapeutics owns a latest Real Value of $26.32 per share. The recent price of the company is $34.55. Our model measures the value of TG Therapeutics from examining the company fundamentals such as Return On Equity of -0.0805, profit margin of (0.05) %, and Current Valuation of 4.76 B as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting TG Therapeutics' valuation include:
Price Book 25.2344 | Enterprise Value 4.8 B | Enterprise Value Ebitda 817.8877 | Price Sales 20.3113 | Forward PE 22.5734 |
Overvalued
Today
Please note that TG Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of TG Therapeutics is based on 3 months time horizon. Increasing TG Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since TG Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of TGTX Stock. However, TG Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 34.55 | Real 26.32 | Target 26.61 | Hype 34.55 | Naive 33.49 |
The intrinsic value of TG Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence TG Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of TG Therapeutics helps investors to forecast how TGTX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of TG Therapeutics more accurately as focusing exclusively on TG Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use TG Therapeutics' intrinsic value based on its ongoing forecasts of TG Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against TG Therapeutics' closest peers.
TG Therapeutics Cash |
|
TGTX Valuation Trend
Analysing the historical paterns of TG Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of TG Therapeutics over time and is usually enough for investors to make rational market timing decisions.
TGTX Revenue by Product
TG Therapeutics Total Value Analysis
TG Therapeutics is at this time anticipated to have valuation of 4.76 B with market capitalization of 5.38 B, debt of 110.8 M, and cash on hands of 195.71 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the TG Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.76 B | 5.38 B | 110.8 M | 195.71 M |
TG Therapeutics Investor Information
About 66.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.1. TG Therapeutics had not issued any dividends in recent years. The entity had 100:5625 split on the 30th of April 2012. Based on the key indicators related to TG Therapeutics' liquidity, profitability, solvency, and operating efficiency, TG Therapeutics is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in December.TG Therapeutics Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of TGTX suggests not a very effective usage of assets in November.TG Therapeutics Ownership Allocation
TG Therapeutics secures a total of 155.66 Million outstanding shares. Over half of TG Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.TG Therapeutics Profitability Analysis
The company reported the previous year's revenue of 233.66 M. Net Income was 12.67 M with profit before overhead, payroll, taxes, and interest of 2.52 M.About TG Therapeutics Valuation
Our relative valuation model uses a comparative analysis of TG Therapeutics. We calculate exposure to TG Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of TG Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 219.1 M | 230.1 M | |
| Pretax Profit Margin | 0.06 | 0.06 | |
| Operating Profit Margin | 0.09 | 0.09 | |
| Net Profit Margin | 0.05 | 0.06 | |
| Gross Profit Margin | 0.94 | 0.98 |
TG Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 148.5 M | |
| Quarterly Earnings Growth Y O Y | -0.973 | |
| Forward Price Earnings | 22.5734 |
TG Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of TG Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value TGTX we look at many different elements of the entity such as TGTX's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as TG Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use TG Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes TG Therapeutics' worth.Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.